EGFR and glioblastoma: In preclinical studies, nimotuzumab showed antiproliferative, proapoptotic, and antiangiogenic effects in tumors that overexpress EGFR 16, and enhanced radiosensitivity with reduction of tumor blood vessels and proliferation in the human GBM cell line U87MG 17.